Recursion Pharmaceuticals Inc. (RXRX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Recursion Pharmaceuticals... (RXRX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.31

-0.43 (-6.38%)

At close: Jan 14, 2025, 3:59 PM

6.35

0.63%

Pre-market Jan 15, 2025, 07:55 AM EST

undefined% (undefined)

Bid	6.34
Market Cap	2.42B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.54
PE Ratio (ttm)	-4.1
Forward PE	n/a
Analyst	Hold

Ask	6.35
Volume	17,135,735
Avg. Volume (20D)	11,646,927
Open	6.95
Previous Close	6.74
Day's Range	6.20 - 6.96
52-Week Range	5.60 - 15.74
Beta	undefined

About RXRX

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 16, 2021

Employees 500

Stock Exchange NASDAQ

Ticker Symbol RXRX

Website https://www.recursion.com

Analyst Forecast

According to 5 analyst ratings, the average rating for RXRX stock is "Hold." The 12-month stock price forecast is $9, which is an increase of 42.63% from the latest price.

Buy 40.00%

Hold 60.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Recursion Pharmaceuticals Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $18.17M, reflecting a 66.84% YoY growth and earnings per share of -0.41, making a -2.38% decrease YoY.

Why Price Moved

4 months ago · Source

Recursion Pharmaceuticals shares are trading lower... Unlock content with Pro Subscription

6 months ago · Source

-13.47%

Recursion Pharmaceuticals shares are trading lower after the company announced the pricing of a $200 million public offering of 30,769,230 shares at $6.50 per share.

News

5 days ago · zacks.com

Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?

The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen...

3 weeks ago · fool.com

Is Recursion Pharmaceuticals Stock a Millionaire Maker?

Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the ...

3 weeks ago · fool.com

1 Artificial Intelligence (AI) Stock That Could Soar in 2025

The artificial intelligence (AI) field has been grabbing many headlines on Wall Street in the past two years. Will this trend continue in 2025?

1 month ago · seekingalpha.com

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The r...

1 month ago · seekingalpha.com

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Recursion Pharmaceuticals, Inc. expects to meet with the FDA to discuss the potential of advancing REC-994 for the treatment of patients with cerebral cavernous malformation. REC-1245 is a CDK12-adjac...

1 month ago · marketbeat.com

NVIDIA Invested in These 2 AI Stocks, Should You?

NVIDIA Co. NASDAQ: NVDA is the undisputed leader of the artificial intelligence (AI) revolution. The company envisioned an AI future over 12 years ago and began executing the blueprint for domination.

1 month ago · fool.com

2 Innovative Stocks That Could Deliver Outsize Returns

2 months ago · zacks.com

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.43 per share a year ago.

2 months ago · fool.com

Is Recursion Pharmaceuticals a Millionaire-Maker Stock?

In an environment where the typical small biotech name is riskier than not, this one is curiously different.

2 months ago · zacks.com

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $6.40, representing a +1.27% change from its previous close.

2 months ago · zacks.com

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.68, signifying a -0.89% move from its prior day's close.

2 months ago · fool.com

3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock

This company stands to benefit from a shifting pharmaceutical industry landscape.

2 months ago · zacks.com

Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know

Recursion Pharmaceuticals (RXRX) reachead $6.36 at the closing of the latest trading day, reflecting a +0.47% change compared to its last close.

3 months ago · fool.com

Prediction: These 2 Stocks Could Soar in 2025

The key word here is "could."

3 months ago · fool.com

Cathie Wood Is Betting on This AI Stock: Is It a Buy?

Wood has a stake in this stock, but it's hardly an "all-in" bet.

3 months ago · fool.com

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing.